Pfizer has licensed access to Enodia Therapeutics’ Sec61 platform in a research collaboration that could be worth more than $500 million. Enodia receives an undisclosed upfront payment and is eligible for research, development and sales milestones plus tiered royalties on net sales. The targets were not disclosed.
The division of labor is conventional platform deal structure. Enodia will screen, optimize and develop Sec61 inhibitor candidates against multiple collaboration targets. Once the research term ends, Pfizer takes over clinical development, manufacturing, regulatory work and commercialization.
Sec61 is the channel through which newly made proteins pass into the endoplasmic reticulum. Modulating it selectively is meant to stop disease driving proteins at the moment of synthesis, before they can act, while leaving essential proteins alone. Enodia’s design engine combines proteomics, cryo-electron microscopy structures and tailored cell line libraries with machine learning, and the company holds chemistry from the Institut Pasteur laboratory of Caroline Demangel and from the Sec61 program it acquired from Kezar Therapeutics. Enodia was launched in February 2025 by Argobio and the Institut Pasteur, which makes a Pfizer deal of this size an unusually fast validation.
The competitive context sharpens it. Eli Lilly recently expanded its own Sec61 collaboration with Gate Bioscience, so both Lilly and Pfizer now hold positions in the same emerging mechanism. None of these programs has human proof of concept yet, and selectivity is the known risk: a channel used by many proteins is a difficult place to achieve a clean therapeutic window. The deal value is therefore best read as the price of an option on a platform, not as revenue visibility for either side.